Demcizumab

Drug Profile

Demcizumab

Alternative Names: Anti-delta-like ligand 4 monoclonal antibody; Anti-DLL4 monoclonal antibody; OMP-18M21; OMP-21M18

Latest Information Update: 24 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Developer Celgene Corporation; OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 08 May 2017 OncoMed Pharmaceuticals suspends patient enrolment in a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom, USA and will conduct a complete program review in the near term with Celgene (IV)
  • 08 May 2017 OncoMed Pharmaceuticals terminates the phase II DENALI trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) and will conduct a complete program review in the near term with Celgene.in USA, Spain, Belgium, Italy, Spain and Germany (IV) (NCT02259582)
  • 08 May 2017 Efficacy and adverse events data from the phase II DENALI trial in Non-small cell lung cancer released by OncoMed Phrmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top